| Recruiting | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants NCT06634589 | BeOne Medicines | Phase 1 / Phase 2 |
| Recruiting | Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) NCT05302037 | CytoMed Therapeutics Pte Ltd | Phase 1 |
| Recruiting | Plan Development for Giving Teclistamab in the Outpatient Setting NCT06251076 | University Health Network, Toronto | Phase 4 |
| Withdrawn | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors NCT06372574 | Genentech, Inc. | Phase 1 |
| Recruiting | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer NCT06208657 | Australian & New Zealand Children's Haematology/Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) L NCT05681195 | Baptist Health South Florida | Phase 2 |
| Recruiting | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC NCT06096038 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035 | Spago Nanomedical AB | Phase 1 / Phase 2 |
| Active Not Recruiting | Individualized Treatments in Adults With Relapsed/Refractory Cancers NCT06024603 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy i NCT05852717 | Dipenkumar Modi | Phase 2 |
| Recruiting | A Study of Avutometinib for People With Solid Tumor Cancers NCT06104488 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations NCT06229340 | N.N. Petrov National Medical Research Center of Oncology | Phase 2 |
| Completed | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractor NCT05990920 | NKGen Biotech, Inc. | Phase 1 |
| Recruiting | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors NCT05958121 | Immatics Biotechnologies GmbH | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid NCT05864144 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981 | Sairopa B.V. | Phase 1 |
| Recruiting | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tu NCT05669430 | GV20 Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody NCT05662397 | HotSpot Therapeutics, Inc | Phase 1 / Phase 2 |
| Terminated | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574 | Biomea Fusion Inc. | Phase 1 |
| Recruiting | Precision Medicine for Every Child With Cancer NCT05504772 | Australian & New Zealand Children's Haematology/Oncology Group | — |
| Unknown | myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports NCT05693831 | Cellworks Group Inc. | — |
| Withdrawn | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors NCT05060276 | Sorrento Therapeutics, Inc. | Phase 1 |
| Recruiting | A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumor NCT07016997 | Chiome Bioscience Inc. | Phase 1 |
| Active Not Recruiting | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor NCT05359445 | Immatics Biotechnologies GmbH | Phase 1 |
| Recruiting | Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma NCT04510636 | University Health Network, Toronto | Phase 2 |
| Completed | A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory G NCT04861987 | Processa Pharmaceuticals | Phase 1 |
| Unknown | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors NCT04859777 | Monopteros Therapeutics Inc. | Phase 1 |
| Completed | Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents NCT04310345 | Vanderbilt-Ingram Cancer Center | N/A |
| Unknown | Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer NCT04840004 | PlusVitech S.L. | Phase 2 |
| Recruiting | Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer NCT04337580 | Wake Forest University Health Sciences | Phase 2 |
| Unknown | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies NCT04640246 | Taiga Biotechnologies, Inc. | Phase 1 / Phase 2 |
| Unknown | Arsenic Trioxide for Structural p53 Mutations NCT04695223 | Shanghai Changzheng Hospital | Phase 2 |
| Terminated | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers NCT04092179 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab, Ibrutinib and Rituximab in PCNSL NCT04421560 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | 9-ING-41 in Pediatric Patients With Refractory Malignancies. NCT04239092 | Actuate Therapeutics Inc. | Phase 1 |
| Completed | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to NCT03941262 | NKGen Biotech, Inc. | Phase 1 |
| Recruiting | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Sol NCT03686124 | Immatics US, Inc. | Phase 1 / Phase 2 |
| Completed | TCR-engineered T Cells in Solid Tumors: IMA202-101 NCT03441100 | Immatics US, Inc. | Phase 1 |
| Completed | Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling NCT03760952 | Immatics US, Inc. | — |
| Completed | Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents NCT03765099 | Vanderbilt-Ingram Cancer Center | N/A |
| Active Not Recruiting | 9-ING-41 in Patients With Advanced Cancers NCT03678883 | Actuate Therapeutics Inc. | Phase 2 |
| Completed | Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS NCT03187288 | University Health Network, Toronto | Phase 1 |
| Completed | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and You NCT03445858 | Children's Hospital Medical Center, Cincinnati | EARLY_Phase 1 |
| Completed | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory NCT03206073 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | PRecISion Medicine for Children With Cancer NCT03336931 | Sydney Children's Hospitals Network | — |
| Unknown | A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer NCT03199677 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggres NCT02747732 | Meirav Kedmi MD | Phase 2 |
| Completed | Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Can NCT02630199 | Samsung Medical Center | Phase 1 |
| Terminated | Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumor NCT02222363 | Vivolux AB | Phase 1 |
| Terminated | BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer NCT01320280 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Unknown | Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment NCT01932047 | Samsung Medical Center | — |
| Completed | A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Pati NCT00551850 | AVEO Pharmaceuticals, Inc. | Phase 1 |
| Completed | Molecular Profiling Protocol (SCRI-CA-001) NCT00530192 | Scottsdale Healthcare | EARLY_Phase 1 |
| Completed | Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric P NCT00011414 | National Cancer Institute (NCI) | Phase 1 |